Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of September 10, 2026, GILD trades at $145.36 with a market cap of $181.83B and a P/E ratio of -56.02. GILD moved -0.20% today. Year to date, GILD is +18.67%; over the trailing twelve months it is +25.82%. Its 52-week range spans $91.69 to $157.29. Analyst consensus is strong buy with an average price target of $158.05. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks GILD insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $145.36 |
| Market Cap | $181.83B |
| P/E Ratio | -56.02 |
| EPS | $-2.60 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $91.69 |
| Volume | 305 |
| Avg Volume | 0 |
| Revenue (TTM) | $30.46B |
| Net Income | $-3.24B |
| Gross Margin | 79.59% |
21 analysts cover GILD: 0 strong buy, 17 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $158.05.